Medtronic (NYSE: MDT) had a strong year in 2025, despite facing challenges such as tariffs impacting its operations. As we move into 2026, there are still compelling reasons to consider investing in this medical technology company, especially for long-term investors seeking steady income.
One significant development for Medtronic is the decision to separate its diabetes business into a standalone, publicly traded entity. This move is expected to be completed by the end of the year, providing Medtronic with the opportunity to focus more on its core business operations. The diabetes care segment has not been as profitable as other areas of the company, and by divesting this division, Medtronic can streamline its operations and potentially unlock more profitable growth opportunities.
Additionally, Medtronic recently received regulatory clearance in the U.S. for its Hugo system, a robotic-assisted surgery device designed for urologic procedures. While this may not have an immediate impact on the company’s financials, it represents a significant long-term opportunity. The market for robotic surgery is still underpenetrated, and as more procedures shift towards minimally invasive techniques, Medtronic is well-positioned to capitalize on this trend.
Furthermore, Medtronic has a strong track record of increasing dividends, with 48 consecutive years of payout hikes. The company currently offers a forward yield of 3%, making it an attractive option for income-seeking investors. With the potential to become a Dividend King in the next couple of years, Medtronic’s commitment to rewarding shareholders is another reason to consider adding this stock to your portfolio.
In conclusion, Medtronic’s strategic initiatives, such as the separation of its diabetes business and the introduction of innovative medical devices like the Hugo system, position the company for long-term success. With a focus on profitable growth opportunities and a history of dividend increases, Medtronic remains a solid investment choice for 2026 and beyond.
